Loading...

One of the most popular stocks in America has lost almost half its value in 2 years

Loading...
One of the most popular stocks in America has lost almost half its value in 2 years - Apa khabar sahabat TIMES NEW MALAYSIA, Dalam artikel yang anda baca kali ini dengan tajuk One of the most popular stocks in America has lost almost half its value in 2 years, kami telah menyediakan dengan baik untuk artikel ini anda membaca dan memuat turun maklumat di dalamnya. mudah-mudahan mengisi jawatan Artikel BOLASEPAK, Artikel NEWS, Artikel PERNIAGAAN, kita menulis ini, anda boleh memahami. Nah, selamat membaca.

Tajuk : One of the most popular stocks in America has lost almost half its value in 2 years
link : One of the most popular stocks in America has lost almost half its value in 2 years

lihat juga


One of the most popular stocks in America has lost almost half its value in 2 years

Gilead

Reuters/Kimberly White

Dr. Albert Liu, director of HIV Prevention Intervention Studies at San Francisco’s Department of Public Health, holds a study pill for his Project T study in San Francisco, California.

According to TD Ameritrade, Gilead Sciences has been one of the most popular stocks with retail investors for years.

Since 2014, the pharmaceutical and biotech company has constantly popped up in TD Ameritrade’s top 10 most commonly owned stocks by retail investors.

Gilead Sciences reported another disappointing quarter after Tuesday’s close, and shares are down about 1.5% on Wednesday. Shares of have lost about 44% since the summer of 2015.

The pharmaceutical giant reported earnings of $2.05 per share on revenue of $6.51 billion. That missed the $2.10 and $6.63 billion that Wall Street analysts were expecting, according to Bloomberg.

Many analysts and investors complain that Gilead is a “one trick pony,” relying too heavily on it’s signature drugs Sovaldi and Harvoni, which can cure Hepatitis-C in just eight weeks, but cost almost $100,000.

Analyst such as Geoffrey Meacham at Barclays, are pushing Gilead to make one or more major acquisitions to fill out their pipeline and diversify past Hepatitis-C. In a letter to management Meacham said, Gilead needs to make “transformational or even incremental transaction.”

“We admire Gilead’s discipline, especially through the valuation peaks and troughs in the biotech/pharma sector, but too much patience has put immense pressure on Gilead shares,” Meachem wrote. “By far and away, our fear is that as quarterly operating cash flow declines … so does Gilead’s capacity to do a meaningful transaction.”

President Trump’s constant call for reduced drug prices has not been helpful to Gilead to say the least. Gilead is considered a poster child for high drug prices.

John F. Milligan took over as CEO from John C. Martin in March of 2016. Milligan is under tremendous pressure to turn Gilead around as the stock soared by about 8,000% under his predecessor.

Click here for a real-time Gilead chart.

Screen Shot 2017 05 03 at 10.05.28 AM

Markets Insider

NOW WATCH: This man spent 6 weeks working undercover in an iPhone factory in China — here’s what it was like

Please enable Javascript to watch this video

Read more stories on Business Insider, Malaysian edition of the world’s fastest-growing business and technology news website.



✍ Sumber Pautan : ☕ Business InsiderBusiness Insider

Kredit kepada pemilik laman asal dan untuk meneruskan bacaan di laman asal sila klik link atau copy paste ke web server : http://ift.tt/2oXzXyG

(✿◠‿◠)✌ Mukah Pages : Pautan Viral Media Sensasi Tanpa Henti. Memuat-naik beraneka jenis artikel menarik setiap detik tanpa henti dari pelbagai sumber. Selamat membaca dan jangan lupa untuk 👍 Like & 💕 Share di media sosial anda!

Gilead

Reuters/Kimberly White

Dr. Albert Liu, director of HIV Prevention Intervention Studies at San Francisco’s Department of Public Health, holds a study pill for his Project T study in San Francisco, California.

According to TD Ameritrade, Gilead Sciences has been one of the most popular stocks with retail investors for years.

Since 2014, the pharmaceutical and biotech company has constantly popped up in TD Ameritrade’s top 10 most commonly owned stocks by retail investors.

Gilead Sciences reported another disappointing quarter after Tuesday’s close, and shares are down about 1.5% on Wednesday. Shares of have lost about 44% since the summer of 2015.

The pharmaceutical giant reported earnings of $2.05 per share on revenue of $6.51 billion. That missed the $2.10 and $6.63 billion that Wall Street analysts were expecting, according to Bloomberg.

Many analysts and investors complain that Gilead is a “one trick pony,” relying too heavily on it’s signature drugs Sovaldi and Harvoni, which can cure Hepatitis-C in just eight weeks, but cost almost $100,000.

Analyst such as Geoffrey Meacham at Barclays, are pushing Gilead to make one or more major acquisitions to fill out their pipeline and diversify past Hepatitis-C. In a letter to management Meacham said, Gilead needs to make “transformational or even incremental transaction.”

“We admire Gilead’s discipline, especially through the valuation peaks and troughs in the biotech/pharma sector, but too much patience has put immense pressure on Gilead shares,” Meachem wrote. “By far and away, our fear is that as quarterly operating cash flow declines … so does Gilead’s capacity to do a meaningful transaction.”

President Trump’s constant call for reduced drug prices

Loading...
has not been helpful to Gilead to say the least. Gilead is considered a poster child for high drug prices.

John F. Milligan took over as CEO from John C. Martin in March of 2016. Milligan is under tremendous pressure to turn Gilead around as the stock soared by about 8,000% under his predecessor.

Click here for a real-time Gilead chart.

Screen Shot 2017 05 03 at 10.05.28 AM

Markets Insider

NOW WATCH: This man spent 6 weeks working undercover in an iPhone factory in China — here’s what it was like

Please enable Javascript to watch this video

Read more stories on Business Insider, Malaysian edition of the world’s fastest-growing business and technology news website.



✍ Sumber Pautan : ☕ Business InsiderBusiness Insider

Kredit kepada pemilik laman asal dan untuk meneruskan bacaan di laman asal sila klik link atau copy paste ke web server : http://ift.tt/2oXzXyG

(✿◠‿◠)✌ Mukah Pages : Pautan Viral Media Sensasi Tanpa Henti. Memuat-naik beraneka jenis artikel menarik setiap detik tanpa henti dari pelbagai sumber. Selamat membaca dan jangan lupa untuk 👍 Like & 💕 Share di media sosial anda!



dengan itu Perkara One of the most popular stocks in America has lost almost half its value in 2 years

yang semua artikel One of the most popular stocks in America has lost almost half its value in 2 years Kali ini, diharapkan dapat memberi manfaat kepada anda semua. Okay, jumpa di lain post artikel.

Kini anda membaca artikel One of the most popular stocks in America has lost almost half its value in 2 years dengan alamat pautan https://timesnewmalaysia.blogspot.com/2017/05/one-of-most-popular-stocks-in-america.html

Subscribe to receive free email updates:

Related Posts :

0 Response to "One of the most popular stocks in America has lost almost half its value in 2 years"

Catat Ulasan

Loading...